Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 3/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25783335 | 0.80 | CCNE2 (0.38) | CCND3CDK6CCNE2CDK1PIM1 | |
| SCHEMBL18937225 | 0.78 | CCNE2 (0.37) | CCND3CDK6CCNE2CDK1PIM1 | |
| SCHEMBL25783843 | 0.78 | — | — | |
| SCHEMBL22824889 | 0.77 | CCND3 (0.39) | CCND3CDK6CCNE2CDK1PIM1 | |
| SCHEMBL25783560 | 0.77 | — | — | |
| SCHEMBL25249556 | 0.73 | — | — | |
| SCHEMBL25783688 | 0.73 | BACE2 (0.32) | — | |
| SCHEMBL25783775 | 0.72 | MAPT (0.30) | — | |
| SCHEMBL25783619 | 0.72 | — | — | |
| SCHEMBL25783782 | 0.72 | BACE2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| CN-113956238-B | Protein kinase inhibitor and preparation method and medical application thereof | 甘李药业股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023116862-A1 | HYDROGENATED INDOLE COMPOUND, AND PREPARATION METHOD AND MEDICAL USE THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116862-A1 | HYDROGENATED INDOLE COMPOUND, AND PREPARATION METHOD AND MEDICAL USE THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-3385262-B1 | 4-(3H-INDOL-5-YL)-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2022-07-13 | — | — | EP | disclosed |
| CN-108290864-B | Protein kinase inhibitor and preparation method and medical application thereof | 甘李药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-113956238-A | Protein kinase inhibitor and preparation method and medical application thereof | 甘李药业股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2021-12-02 | — | — | US | disclosed |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2021-12-02 | — | — | US | disclosed |
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS | 2021-08-17 | — | — | US | disclosed |
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS | 2021-08-17 | — | — | US | disclosed |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3385262-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD AND MEDICAL USE THEREOF | Gan & Lee Pharmaceuticals (CN) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017092635-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD AND MEDICAL USE THEREOF | 甘李药业股份有限公司 | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | CCND3 440/4885CDK6 56/4885CCNE2 1305/4885 |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | ROR1, DMPK, CDK9 | CCND3 440/4885CDK6 56/4885CCNE2 1305/4885 |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | ROR1, DMPK, CDK9 | CCND3 440/4885CDK6 56/4885CCNE2 1305/4885 |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | CCND3 440/4885CDK6 56/4885CCNE2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.